FDA probes new pancreas risks with diabetes drugs - New York News

FDA probes new pancreas risks with diabetes drugs

Posted: Updated:

By MATTHEW PERRONE, AP Health Writer

WASHINGTON (AP) — The Food and Drug Administration is looking into new evidence that suggests a group of recently approved diabetes drugs can increase the risk of pancreatitis and other problems.

The agency said Thursday samples of pancreas tissue taken from a small number of patients showed inflammation and cellular changes that often precede cancer. Academic researchers took the samples from diabetes patients who were taking the new medications, after they died from various causes.

Details of the research have not yet been published, but the agency said in an online statement it is seeking more information.

While the FDA has issued previous alerts about the pancreatitis risk, the agency had not notified the public about pre-cancerous cell changes seen with the drugs.

For now, regulators say they are still investigating the issue.

"FDA has not concluded these drugs may cause or contribute to the development of pancreatic cancer," the agency said in an online statement. "At this time, patients should continue to take their medicine as directed until they talk to their health care professional."

The drugs under review come from a wave of recently approved diabetes medications, including Merck's Januvia and Janumet, Novo Nordisk's Victoza and Bristol-Myers Squibb's Byetta and Bydureon, among others. All the drugs mimic natural hormones that the body usually produces to spur insulin production after a meal.

Citi Investment Research analyst Andrew Baum told investors the investigation would likely have "minimal impact" on drug sales.  Similar investigations in recent years have not resulted in safety restrictions, he says.

"We believe that the likely worst case for the market incumbents is that the FDA could add additional warnings about increased risk of pancreas-related adverse events" Baum stated in a research note.

People with type 2 diabetes are unable to properly break down carbohydrates, either because their bodies do not produce enough insulin or because they've become resistant to the hormone, which controls blood sugar levels. These patients are at higher risk for heart attacks, kidney problems, blindness and other serious complications.

Many diabetics require multiple drugs with different mechanisms of action to control their blood sugar levels.

With more than 25 million people living with diabetes in the U.S., some of the world's biggest drugmakers have launched new treatments in recent years, though safety questions have emerged.

The FDA previously added information about cases of pancreatitis, some of them fatal, to the labels of Byetta in 2007, and Januvia and Janumet in 2009.

A recent study of insurance records found that use of those drugs could double the risk of developing acute pancreatitis, according to the FDA.

Januvia is a once-a-day pill. Janumet combines the drug with metformin, a decades-old drug commonly prescribed for diabetes. Byetta is a twice-a-day injection originally developed by Amylin Pharmaceuticals. Bristol-Myers acquired the drug last year, along with the newer formulation Bydureon, which is taken once-a-week.

Byetta and Bydureon are part of a drug class that mimics the GLP-1 hormone, triggering insulin production after a meal.

Januvia and Janumet work by blocking the DPP-4 enzyme, which spurs release of more insulin from the pancreas. Those drugs brought in a total of about $5.75 billion last year, making them Merck's biggest franchise.

The pancreas produces various hormones, including insulin, that help the body break down sugar. Pancreatitis causes an inflammation of the organ and can lead to fatal complications, including difficulty breathing and kidney failure.

Shares of Whitehouse Station, N.J.-based Merck & Co. Inc. fell 32 cents to $44.27. Shares of New York-based Bristol-Myers Squibb Co. declined 1 cent to $38.48.

AP Business Writer Linda A. Johnson contributed to this story from Trenton, N.J.

--- 

A look at the diabetes drugs under investigation by the U.S.  Food and Drug Administration over possible risks of pancreas inflammation and cellular changes in the pancreas that occur before cancer.

DRUG CLASS: GLP-1 mimickers, taken by nearly 1 million Americans.

HOW THEY WORK: Injections needed anywhere from twice a day to once a week, they make the body produce more insulin to lower blood sugar.

MAKER: Bristol-Myers Squibb Co.

CHEMICAL/BRAND NAMES: exenatide/Byetta and Bydureon

MAKER: Novo Nordisk A/S:

CHEMICAL/BRAND NAMES: liraglutide/Victoza

___

DRUG CLASS: DPP-4 inhibitors, taken by about 1.6 million Americans.

HOW THEY WORK: Pills taken once or twice a day, they stimulate insulin production and limit release of a hormone that raises blood sugar levels.

MAKER: Merck & Co.

CHEMICAL/BRAND NAMES: sitagliptin/Januvia, Janumet, Janumet XR, Juvisync

MAKER: Bristol-Myers Squibb Co. & AstraZeneca PLC

CHEMICAL/BRAND NAMES:  saxagliptin/Onglyza and Kombiglyze

MAKER: Eli Lilly and Co. and  Boehringer Ingelheim Pharmaceuticals Inc.

CHEMICAL/BRAND NAMES: linagliptin/Jentadueto and Tradjenta

MAKER: Takeda Pharmaceuticals Co. Ltd.

CHEMICAL/BRAND NAMES: alogliptin/Nesina, Kazano and Oseni

___

Source: Company websites, health data firm Kantar Health.

Copyright 2013 The Associated Press.

  • HealthMore>>

  • FDA Approves Blood Test to Aid Diagnosis of Type 1 Diabetes

    FDA Approves Blood Test to Aid Diagnosis of Type 1 Diabetes

    FDA Approves Blood Test to Aid Diagnosis of Type 1 Diabetes Type 1 diabetes blood test detects unique autoantibody (dailyRx News) While Type 1 and Type 2 diabetes share some traits, treatments for each condition...
    FDA Approves Blood Test to Aid Diagnosis of Type 1 Diabetes Type 1 diabetes blood test detects unique autoantibody (dailyRx News) While Type 1 and Type 2 diabetes share some traits, treatments for each...
  • Reversing Prediabetes May Be a Heart Saver

    Reversing Prediabetes May Be a Heart Saver

    Reversing Prediabetes May Be a Heart Saver Diabetes and heart disease risk drops in prediabetes patients who regain normal blood sugar (dailyRx News) Blood sugar levels that are high but not high...
    Reversing Prediabetes May Be a Heart Saver Diabetes and heart disease risk drops in prediabetes patients who regain normal blood sugar (dailyRx News) Blood sugar levels that are high but not high enough to...
  • Do you have a soul mate?

    Do you have a soul mate?

    Tuesday, August 26 2014 10:25 PM EDT2014-08-27 02:25:51 GMT
    Fox 5 found that romance is almost completely alive and well in Harlem. The notion of one a soul mate, your better half, the one and only is thriving. Maybe have Cinderella or rather reality television to thank for this notion.Sadly, new research shows if you believe your partner is your soul mate your expectations may be to high when times get tough.
    Fox 5 found that romance is almost completely alive and well in Harlem. The notion of one a soul mate, your better half, the one and only is thriving. Maybe have Cinderella or rather reality television to thank for this notion.Sadly, new research shows if you believe your partner is your soul mate your expectations may be to high when times get tough.
  • Local NewsLocal NewsMore>>

  • NJ girl accidentally kills gun instructor

    NJ girl accidentally kills gun instructor

    Tuesday, August 26 2014 7:12 PM EDT2014-08-26 23:12:52 GMT
    A 9-year-old girl from New Jersey accidentally killed an Arizona shooting instructor as he was showing her how to use a fully automatic Uzi, authorities said Tuesday. Charles Vacca, 39, of Lake Havasu City, died Monday shortly after being airlifted to University Medical Center in Las Vegas, Mohave County sheriff's officials said.
    A 9-year-old girl from New Jersey accidentally killed an Arizona shooting instructor as he was showing her how to use a fully automatic Uzi, authorities said Tuesday. Charles Vacca, 39, of Lake Havasu City, died Monday shortly after being airlifted to University Medical Center in Las Vegas, Mohave County sheriff's officials said.
  • Fighting street harassment

    Fighting street harassment

    Tuesday, August 26 2014 6:37 PM EDT2014-08-26 22:37:24 GMT
    New York City women are tired of hearing vile things yelled at them as they walk down the street. Many women are going public about street harassment and catcalling. Some even post picture of their offenders on social media. Founded in 2005, Hollaback! is an anti-harassment organization giving women a platform to do just that.
    New York City women are tired of hearing vile things yelled at them as they walk down the street. Many women are going public about street harassment and catcalling. Some even post picture of their offenders on social media. Founded in 2005, Hollaback! is an anti-harassment organization giving women a platform to do just that.
  • Street Stories

    NYC homelessness and panhandling

    NYC homelessness and panhandling

    Tuesday, August 26 2014 5:08 PM EDT2014-08-26 21:08:08 GMT
    Homeless people still sleep under the Manhattan Bridge, but others who used to camp out near its base have been displaced by police and are now calling Park Avenue South home. Park Avenue South sits in one of the trendiest parts of Manhattan, with businesses, restaurants, hotels, and swank lofts. It's also the street corner home base of Tommy Lanfranchi and his domestic partner Nicole Kilroy, who've been in a methadone program for 10 years.
    Homeless people still sleep under the Manhattan Bridge, but others who used to camp out near its base have been displaced by police and are now calling Park Avenue South home. Park Avenue South sits in one of the trendiest parts of Manhattan, with businesses, restaurants, hotels, and swank lofts. It's also the street corner home base of Tommy Lanfranchi and his domestic partner Nicole Kilroy, who've been in a methadone program for 10 years.
Powered by WorldNow
Didn't find what you were looking for?
All content © Copyright 2000 - 2014 Fox Television Stations, Inc. and Worldnow. All Rights Reserved.
Privacy Policy | New Terms of Service What's new | Ad Choices